256 related articles for article (PubMed ID: 26038829)
21. Mitochondrial Delivery of Doxorubicin Using MITO-Porter Kills Drug-Resistant Renal Cancer Cells via Mitochondrial Toxicity.
Yamada Y; Munechika R; Kawamura E; Sakurai Y; Sato Y; Harashima H
J Pharm Sci; 2017 Sep; 106(9):2428-2437. PubMed ID: 28478130
[TBL] [Abstract][Full Text] [Related]
22. Liposomal doxorubicin attenuates cardiotoxicity via induction of interferon-related DNA damage resistance.
Gyöngyösi M; Lukovic D; Zlabinger K; Spannbauer A; Gugerell A; Pavo N; Traxler D; Pils D; Maurer G; Jakab A; Riesenhuber M; Pircher A; Winkler J; Bergler-Klein J
Cardiovasc Res; 2020 Apr; 116(5):970-982. PubMed ID: 31346605
[TBL] [Abstract][Full Text] [Related]
23. Mitochondrial targeted antioxidants, mitoquinone and SKQ1, not vitamin C, mitigate doxorubicin-induced damage in H9c2 myoblast: pretreatment vs. co-treatment.
Sacks B; Onal H; Martorana R; Sehgal A; Harvey A; Wastella C; Ahmad H; Ross E; Pjetergjoka A; Prasad S; Barsotti R; Young LH; Chen Q
BMC Pharmacol Toxicol; 2021 Sep; 22(1):49. PubMed ID: 34530934
[TBL] [Abstract][Full Text] [Related]
24. Charge Reversible and Mitochondria/Nucleus Dual Target Lipid Hybrid Nanoparticles To Enhance Antitumor Activity of Doxorubicin.
Song YF; Liu DZ; Cheng Y; Teng ZH; Cui H; Liu M; Zhang BL; Mei QB; Zhou SY
Mol Pharm; 2018 Mar; 15(3):1296-1308. PubMed ID: 29432025
[TBL] [Abstract][Full Text] [Related]
25. HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity.
Reynolds JG; Geretti E; Hendriks BS; Lee H; Leonard SC; Klinz SG; Noble CO; Lücker PB; Zandstra PW; Drummond DC; Olivier KJ; Nielsen UB; Niyikiza C; Agresta SV; Wickham TJ
Toxicol Appl Pharmacol; 2012 Jul; 262(1):1-10. PubMed ID: 22676972
[TBL] [Abstract][Full Text] [Related]
26. Effect of hypothermia on doxorubicin-induced cardiac myoblast signaling and cell death.
L'Ecuyer TJ; Aggarwal S; Zhang JP; Van der Heide RS
Cardiovasc Pathol; 2012; 21(2):96-104. PubMed ID: 21489822
[TBL] [Abstract][Full Text] [Related]
27. Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma.
Buondonno I; Gazzano E; Jean SR; Audrito V; Kopecka J; Fanelli M; Salaroglio IC; Costamagna C; Roato I; Mungo E; Hattinger CM; Deaglio S; Kelley SO; Serra M; Riganti C
Mol Cancer Ther; 2016 Nov; 15(11):2640-2652. PubMed ID: 27466354
[TBL] [Abstract][Full Text] [Related]
28. Mitochondrial delivery of doxorubicin via triphenylphosphine modification for overcoming drug resistance in MDA-MB-435/DOX cells.
Han M; Vakili MR; Soleymani Abyaneh H; Molavi O; Lai R; Lavasanifar A
Mol Pharm; 2014 Aug; 11(8):2640-9. PubMed ID: 24811541
[TBL] [Abstract][Full Text] [Related]
29. Reduction of doxorubicin-induced cytotoxicity and mitochondrial damage by betanin in rat isolated cardiomyocytes and mitochondria.
Hafez AA; Jamali Z; Samiei S; Khezri S; Salimi A
Hum Exp Toxicol; 2021 Dec; 40(12):2123-2134. PubMed ID: 34105389
[TBL] [Abstract][Full Text] [Related]
30. Paradoxically, iron overload does not potentiate doxorubicin-induced cardiotoxicity in vitro in cardiomyocytes and in vivo in mice.
Guenancia C; Li N; Hachet O; Rigal E; Cottin Y; Dutartre P; Rochette L; Vergely C
Toxicol Appl Pharmacol; 2015 Apr; 284(2):152-62. PubMed ID: 25711856
[TBL] [Abstract][Full Text] [Related]
31. LncRNA FOXC2-AS1 protects cardiomyocytes from doxorubicin-induced cardiotoxicity through activation of WNT1-inducible signaling pathway protein-1.
Zhang S; Yuan Y; Zhang Z; Guo J; Li J; Zhao K; Qin Y; Qiu C
Biosci Biotechnol Biochem; 2019 Apr; 83(4):653-658. PubMed ID: 30558506
[TBL] [Abstract][Full Text] [Related]
32. BGP-15 Protects against Doxorubicin-Induced Cell Toxicity via Enhanced Mitochondrial Function.
Gyongyosi A; Csaki N; Peto A; Szoke K; Fenyvesi F; Bacskay I; Lekli I
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982341
[TBL] [Abstract][Full Text] [Related]
33. Toll-like receptor 5 deficiency diminishes doxorubicin-induced acute cardiotoxicity in mice.
Ma ZG; Kong CY; Wu HM; Song P; Zhang X; Yuan YP; Deng W; Tang QZ
Theranostics; 2020; 10(24):11013-11025. PubMed ID: 33042267
[No Abstract] [Full Text] [Related]
34. [The in vitro cytotoxicity and in vivo toxicity of doxorubicin antiresistant stealth liposomes].
Wang JC; Liu XY; Lü WL; Lee HS; Goh BC; Zhang Q
Yao Xue Xue Bao; 2005 May; 40(5):475-80. PubMed ID: 16220797
[TBL] [Abstract][Full Text] [Related]
35. Protective effects of mito-TEMPO against doxorubicin cardiotoxicity in mice.
Rocha VC; França LS; de Araújo CF; Ng AM; de Andrade CM; Andrade AC; Santos Ede S; Borges-Silva Mda C; Macambira SG; Noronha-Dutra AA; Pontes-de-Carvalho LC
Cancer Chemother Pharmacol; 2016 Mar; 77(3):659-62. PubMed ID: 26712129
[TBL] [Abstract][Full Text] [Related]
36. Influence of PARP-1 inhibition in the cardiotoxicity of the topoisomerase 2 inhibitors doxorubicin and mitoxantrone.
Damiani RM; Moura DJ; Viau CM; Brito V; Morás AM; Henriques JAP; Saffi J
Toxicol In Vitro; 2018 Oct; 52():203-213. PubMed ID: 29913208
[TBL] [Abstract][Full Text] [Related]
37. Honokiol protects against doxorubicin cardiotoxicity via improving mitochondrial function in mouse hearts.
Huang L; Zhang K; Guo Y; Huang F; Yang K; Chen L; Huang K; Zhang F; Long Q; Yang Q
Sci Rep; 2017 Sep; 7(1):11989. PubMed ID: 28931882
[TBL] [Abstract][Full Text] [Related]
38. Sesamin ameliorates doxorubicin-induced cardiotoxicity: involvement of Sirt1 and Mn-SOD pathway.
Su S; Li Q; Liu Y; Xiong C; Li J; Zhang R; Niu Y; Zhao L; Wang Y; Guo H
Toxicol Lett; 2014 Jan; 224(2):257-63. PubMed ID: 24211423
[TBL] [Abstract][Full Text] [Related]
39. Ghrelin inhibits doxorubicin cardiotoxicity by inhibiting excessive autophagy through AMPK and p38-MAPK.
Wang X; Wang XL; Chen HL; Wu D; Chen JX; Wang XX; Li RL; He JH; Mo L; Cen X; Wei YQ; Jiang W
Biochem Pharmacol; 2014 Apr; 88(3):334-50. PubMed ID: 24522112
[TBL] [Abstract][Full Text] [Related]
40. Early Cardiac Mitochondrial Molecular and Functional Responses to Acute Anthracycline Treatment in Wistar Rats.
Pereira GC; Pereira SP; Pereira FB; Lourenço N; Lumini JA; Pereira CV; Bjork JA; Magalhães J; Ascensão A; Wieckowski MR; Moreno AJ; Wallace KB; Oliveira PJ
Toxicol Sci; 2019 May; 169(1):137-150. PubMed ID: 30698778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
